Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 7, 2003
- 290 Reclassified Quasi-drugs Had Sales of \105 Bil. in 10 Months
April 7, 2003
- New Medical Fee Payment System Proposed
April 7, 2003
- AnGes MG Embarks on Joint Research with Osaka Univ., Shimadzu
April 7, 2003
- OTC NEWS IN BUEF
April 7, 2003
- Basic Policy for Medical Insurance, Medical Fee Payment System Reform Approved by LDP
April 7, 2003
- Sosei, Abgenix to Codevelop Antibodies against CRTh2
April 7, 2003
- Mitsubishi Kagaku Medical, Iatron, Dia-Iatron to Be Integrated in July
April 7, 2003
- NHI Listing for 4 Active Ingredients Including Sevelamer HCl
April 7, 2003
- Kyowa Hakko Starts Large Clinical Study on Coniel in Japan
April 7, 2003
- DIAGNOSTIC NEWS IN BRIEF
April 7, 2003
- Cabinet Draft Decision Calls For Measures to Expand Patient Choice: Deregulation Plan
April 7, 2003
- Data on Similar Drugs Required for Risk Benefit Analysis: RAD-AR Council Japan
April 7, 2003
- Nihon Schering Publishes Its 50-year History
April 7, 2003
- Korosho Issues Checklist to Promote GE Drug Use in Nat'l Hospital
April 7, 2003
- Atypical Antipsychotic Agents Useful in Maintenance Therapy
April 7, 2003
- MEDICAL DEVICE NEWS IN BRIEF
April 7, 2003
- Proposed Basic Policy Calls For Operation of Health Insurance Programs by Prefecture
April 7, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 7, 2003
- WORLD NEWS IN BRIEF
April 7, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…